The National Association of Chain 91短视频 Stores reports that final average manufacturer price (AMP)-based federal upper limits (FULs) are set to be published by the Centers for Medicare & Medicaid Services (CMS) late this month.
Once instituted, the final AMP-based FULs will 鈥渟ignificantly change鈥� Medicaid pharmacy reimbursement for branded and generic drugs, according to NACDS.
CMS issued the with comment in January. The rule (CMS-2345-FC) addresses and changes made to the Medicaid 91短视频 Rebate Program by the Affordable Care Act.
NACDS noted that it鈥檚 continuing to work with in-state partners to assess state activities on the implementation of the upcoming finalized AMP-based FULs, the adoption of the cost-based reimbursement provisions of the final rule, and the transition to 鈥渇air and accurate鈥� dispensing fees. The association, too, said it鈥檚 looking at how states have implemented acquisition cost-based reimbursement.
Final AMP-based FULs go into effect on April 1. Once the rule is published, states will have up to 30 days from the April 1 effective date to implement the FULs, but NACDS noted that states will have until April 2017 to move to cost-based product reimbursement and adjust dispensing fees.
